ELOVL1-IN-3
Based on 2 publication(s) in Google Scholar
ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD)[1].
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 2761063-99-2
- Formule: C21H23N5O2
- Masse moléculaire:377.44
-
Stockage:Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ELOVL1-IN-3
More
Activité biologique
ELOVL1[1]
ELOVL1-IN-3 (100 nM, 48 hours) selectively inhibits ELOVL1-mediated C26:0 LPC synthesis in HEK293 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ATP binding cassette transporter D1 (ABCD1) knockout mouse model (Adrenoleukodystrophy (ALD) disease)[1]
-
Dosage:1, 4, 8, 16, or 32 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 3 months
-
Result:Significantly reduced blood C26:0 LPC levels (8 mg/kg or higher brought levels near wild-type).
-
Animal Model:Sprague-Dawley rats
-
Dosage:10 or 50 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 28 days
-
Result:Reduced blood C26:0 LPC levels by 78% and 79%, respectively.
-
Animal Model:Cynomolgus monkey
-
Dosage:6.5 or 50 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 14 days
-
Result:Reduced blood C26:0 LPC levels by 47% and 65%, respectively.
Chemical Information
-
CAS No. 2761063-99-2
-
Appearance Oil
-
Masse moléculaire 377.44
-
Formule C21H23N5O2
-
Color Colorless to light yellow
-
SMILES
[C@@H]1(C2=CC=CC=C2)OCCN(C3=CC(O[C@@H]4C[C@H](N5C=CC=N5)C4)=NC=N3)C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Transcription factor 19 modulates fatty acid elongation and unfolded protein response to attenuate palmitic acid-induced hepatic dysfunction. [Abstract]2026 Apr 22;17(1):5596. PMID: 42020413 -
Solvant et solubilité
DMSO : 100 mg/mL (264.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6494 mL | 13.2471 mL | 26.4943 mL | 66.2357 mL |
| 5 mM | 0.5299 mL | 2.6494 mL | 5.2989 mL | 13.2471 mL | |
| 10 mM | 0.2649 mL | 1.3247 mL | 2.6494 mL | 6.6236 mL | |
| 15 mM | 0.1766 mL | 0.8831 mL | 1.7663 mL | 4.4157 mL | |
| 20 mM | 0.1325 mL | 0.6624 mL | 1.3247 mL | 3.3118 mL | |
| 25 mM | 0.1060 mL | 0.5299 mL | 1.0598 mL | 2.6494 mL | |
| 30 mM | 0.0883 mL | 0.4416 mL | 0.8831 mL | 2.2079 mL | |
| 40 mM | 0.0662 mL | 0.3312 mL | 0.6624 mL | 1.6559 mL | |
| 50 mM | 0.0530 mL | 0.2649 mL | 0.5299 mL | 1.3247 mL | |
| 60 mM | 0.0442 mL | 0.2208 mL | 0.4416 mL | 1.1039 mL | |
| 80 mM | 0.0331 mL | 0.1656 mL | 0.3312 mL | 0.8279 mL | |
| 100 mM | 0.0265 mL | 0.1325 mL | 0.2649 mL | 0.6624 mL |
ELOVL1-IN-3 Related Classifications
HY-145272 Related Classifications
Powered by Bioz